2834 – Page 93 – China Stock Advice

TPI [TIANYIN PHARMACEUTICAL] POS AM: (Original Filing)

[Post Effective Amendment No.5 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Tianyin Pharmaceutical Co., Inc. Delaware (State or other jurisdiction of incorporation or organization) 20-4857782 (I.R.S. Employer Identification No.) 23rd Floor, Unionsun Yangkuo Plaza, No. 2, Block 3 Renmin Road South, Chengdu, P. R. China, 610041 +0086-28-86154737 Dr. Guoqing Jiang, Chief Executive Officer Tianyin Pharmaceutical Co.,] [HUNTER TAUBMAN WEISS LLP 130 w. 42nd Street, Suite 1050 New York, New York 10036 (212) 732-7184 Fax: (212) 202-6380 E-mail: LTaubman@htwlaw.com July 1, 2013 Tianyin Pharmaceutical Co., Inc. 23rd Floor, Unionsun Yangkuo Plaza No. 2, Block 3, Renmin Road South Chengdu, P. R. China, 610041 Ladies and Gentlemen: Sincerely, HUNTER TAUBMAN WEISS LLP Louis E. Taubman EX-5.1 2 posam2013a5ex5i_tianyin.htm] [Patrizio & Zhao, LLC Certified Public Accountants and Consultants 322 Route 46 West Parsippany, NJ 07054 Fax: (973) 882-0788 www.pzcpa.com Member of Alliance of worldwide accounting firms CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We consent to the use in the Post-Effective Amendment No. 5 to a Registration Statement on Form S-1 pertaining to the registration of 12,559,099 shares of]

By info| 2016-03-27T18:18:39+00:00 July 1st, 2013|Categories: Chinese Stocks, SEC Original, TPI|Tags: 0001362718, 2013-07-01, 2834, PHARMACEUTICAL PREPARATIONS, POS_AM, TPI|0 Comments

TPI [TIANYIN PHARMACEUTICAL] POS AM: Post Effective Amendment No.5 to FORM S-1 REGISTRATION

[Post Effective Amendment No.5 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Tianyin Pharmaceutical Co., Inc. Delaware (State or other jurisdiction of incorporation or organization) 20-4857782 (I.R.S. Employer Identification No.) 23rd Floor, Unionsun Yangkuo Plaza, No. 2, Block 3 Renmin Road South, Chengdu, P. R. China, 610041 +0086-28-86154737 Dr. Guoqing Jiang, Chief Executive Officer Tianyin Pharmaceutical Co.,] [HUNTER TAUBMAN WEISS LLP 130 w. 42nd Street, Suite 1050 New York, New York 10036 (212) 732-7184 Fax: (212) 202-6380 E-mail: LTaubman@htwlaw.com July 1, 2013 Tianyin Pharmaceutical Co., Inc. 23rd Floor, Unionsun Yangkuo Plaza No. 2, Block 3, Renmin Road South Chengdu, P. R. China, 610041 Ladies and Gentlemen: Sincerely, HUNTER TAUBMAN WEISS LLP Louis E. Taubman EX-5.1 2 posam2013a5ex5i_tianyin.htm] [Patrizio & Zhao, LLC Certified Public Accountants and Consultants 322 Route 46 West Parsippany, NJ 07054 Fax: (973) 882-0788 www.pzcpa.com Member of Alliance of worldwide accounting firms CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We consent to the use in the Post-Effective Amendment No. 5 to a Registration Statement on Form S-1 pertaining to the registration of 12,559,099 shares of]

By info| 2016-03-27T18:19:41+00:00 July 1st, 2013|Categories: Chinese Stocks, TPI, Webplus ver|Tags: 0001362718, 2013-07-01, 2834, PHARMACEUTICAL PREPARATIONS, POS_AM, TPI|0 Comments

SVA [SINOVAC BIOTECH] 6-K: Sinovac Reports Unaudited First Quarter 2013 Financial Results

[Sinovac Reports Unaudited First Quarter 2013 Financial Results -Conference call scheduled for Tuesday, May 28, 2013 at 8:00 AM EDT - BEIJING, May 28, 2013 /PRNewswire/ — Sinovac Biotech Ltd. (SVA), a leading provider of biopharmaceutical products in China, announced today its unaudited first quarter financial results for the period ended March 31, 2013. First Quarter 2013 Financial Highlights (Year-over-year] [Sinovac Files New Drug Application for EV71 Vaccine and Receives Filing Acceptance from Beijing Drug Administration BEIJING, May 30, 2013 /PRNewswire/ — Sinovac Biotech Ltd. (SVA), a leading provider of biopharmaceutical products in China, today announced Sinovac's new drug application (NDA) for its proprietary EV71 vaccine has been filed and accepted by the Beijing Drug Administration. In terms of next] [Sinovac Appoints New Chief Financial Officer Vice President of Sinovac Named CFO BEIJING, May 31, 2013 /PRNewswire/ — Sinovac Biotech Ltd. (SVA), a leading provider of biopharmaceutical products in China, announced today that Ms. Nan Wang, Vice President of Sinovac, has been appointed as Chief Financial Officer, effective June 1, 2013. Mr. Danny Chung, who was Chief Financial Officer, has] []

By info| 2016-03-24T00:21:35+00:00 June 3rd, 2013|Categories: Chinese Stocks, SVA, Webplus ver|Tags: 0001084201, 2013-06-03, 2834, 6-K, PHARMACEUTICAL PREPARATIONS, SVA|0 Comments

SVA [SINOVAC BIOTECH] 6-K: (Original Filing)

[Sinovac Reports Unaudited First Quarter 2013 Financial Results -Conference call scheduled for Tuesday, May 28, 2013 at 8:00 AM EDT - BEIJING, May 28, 2013 /PRNewswire/ — Sinovac Biotech Ltd. (SVA), a leading provider of biopharmaceutical products in China, announced today its unaudited first quarter financial results for the period ended March 31, 2013. First Quarter 2013 Financial Highlights (Year-over-year] [Sinovac Files New Drug Application for EV71 Vaccine and Receives Filing Acceptance from Beijing Drug Administration BEIJING, May 30, 2013 /PRNewswire/ — Sinovac Biotech Ltd. (SVA), a leading provider of biopharmaceutical products in China, today announced Sinovac's new drug application (NDA) for its proprietary EV71 vaccine has been filed and accepted by the Beijing Drug Administration. In terms of next] [Sinovac Appoints New Chief Financial Officer Vice President of Sinovac Named CFO BEIJING, May 31, 2013 /PRNewswire/ — Sinovac Biotech Ltd. (SVA), a leading provider of biopharmaceutical products in China, announced today that Ms. Nan Wang, Vice President of Sinovac, has been appointed as Chief Financial Officer, effective June 1, 2013. Mr. Danny Chung, who was Chief Financial Officer, has] []

By info| 2016-03-24T00:20:20+00:00 June 3rd, 2013|Categories: Chinese Stocks, SEC Original, SVA|Tags: 0001084201, 2013-06-03, 2834, 6-K, PHARMACEUTICAL PREPARATIONS, SVA|0 Comments

SVA [SINOVAC BIOTECH] 6-K: (Original Filing)

[Sinovac Beijing Obtains China GMP Certificate Under the New GMP Guidelines Beijing – May 24, 2013 – Sinovac Biotech Ltd. (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced that Sinovac Beijing, the main operating subsidiary company of Sinovac, obtained the Certificate of Good Manufacturing Practices for Pharmaceutical Products (GMP Certificate) from the China State and Food Administration] []

By info| 2016-03-24T00:30:41+00:00 May 24th, 2013|Categories: Chinese Stocks, SEC Original, SVA|Tags: 0001084201, 2013-05-24, 2834, 6-K, PHARMACEUTICAL PREPARATIONS, SVA|0 Comments

SVA [SINOVAC BIOTECH] 6-K: Sinovac Beijing Obtains China GMP Certificate Under the

[Sinovac Beijing Obtains China GMP Certificate Under the New GMP Guidelines Beijing – May 24, 2013 – Sinovac Biotech Ltd. (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced that Sinovac Beijing, the main operating subsidiary company of Sinovac, obtained the Certificate of Good Manufacturing Practices for Pharmaceutical Products (GMP Certificate) from the China State and Food Administration] []